The Investigational Drug Service (IDS), directed by Barbara Todaro, PharmD, plays a critical role in RPCI research. IDS staff members are responsible for all aspects of investigational drug management, including accountability, ordering, receiving, destruction, returns, proper storage and dispensing. IDS pharmacists provide medication counseling for patients enrolled in clinical research studies. They also provide medication reconciliation for patients in screening for a research study, and this is documented, in the electronic medical record (EMR). The number and complexity of research studies, especially Phase 1 studies, were the driving forces behind the creation of IDS by the Department of Pharmacy and the Clinical Protocol and Data Management (CPDM) office. Eight (8) FTEs are required to support all RPCI clinical research studies. Responsibilities of IDS staff include study review for SRC and IRB submission, amendment review, review of amended investigator brochures, study implementation, dispensing and sterile products preparation, and clinical services such as medication review and patient counseling. An IDS staff member is also involved with implementation of Investigator-Initiated studies in the RPCI Clinical Research Network. IDS staff members provide expert consultation for each clinical research study utilizing pharmaceutical products. Dr. Todaro is the Co-Chair of the Phase 1 Committee and has provided consultation for thirty-five Phase I Investigator-Initiated studies during the previous award period. Under Dr. Todaro's direction, the reporting processes for adverse events, dose limiting toxicities and phase 1 patient monitoring have been updated to provide the Institutional Review Board (IRB) with necessary critical information in a timely manner. At the time of this submission, IDS was responsible for more than 300 investigational items, with 150 investigational drugs or items for 80 clinical research studies. A member of IDS attends all study initiation meetings. There were 53 implementation meetings for clinical research studies in 2012. Utilization of IDS resources is prioritized as follows: First priority for use is given to peer-review-funded RPCI CCSG members;second priority to non-peer-review-funded CCSG members;third priority to nonmembers and academic collaborators;and last priority to external users. During the reporting period, IDS served 28 members from 6 research programs, with 63% utilization by CCSG members with peer reviewed funding. The CCSG makes up 3% of the overall proposed budget. This application seeks 0.14 FTE support for the Director, with staffing support to be provided by institutional sources as well as study sponsors (NIH/CTEP, industry, foundations).

Public Health Relevance

Accurate drug preparation and accountability, as well as dosage dispensing, are essential to ensuring scientifically valid clinical research. IDS is a centralized specialized resource that performs a full scope of activities to assist investigators with medication preparation, distribution, monitoring, and documentation to facilitate effective and efficient conduct of clinical research studies.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Roswell Park Cancer Institute Corp
United States
Zip Code
Ciamporcero, Eric; Miles, Kiersten Marie; Adelaiye, Remi et al. (2015) Combination strategy targeting VEGF and HGF/c-met in human renal cell carcinoma models. Mol Cancer Ther 14:101-10
Ma, Yingyu; Hu, Qiang; Luo, Wei et al. (2015) 1?,25(OH)2D3 differentially regulates miRNA expression in human bladder cancer cells. J Steroid Biochem Mol Biol 148:166-71
Shen, Li; Sundstedt, Anette; Ciesielski, Michael et al. (2015) Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. Cancer Immunol Res 3:136-48
Adelaiye, Remi; Ciamporcero, Eric; Miles, Kiersten Marie et al. (2015) Sunitinib dose escalation overcomes transient resistance in clear cell renal cell carcinoma and is associated with epigenetic modifications. Mol Cancer Ther 14:513-22
Uekusa, Shota; Kawashima, Hiroyuki; Sugito, Kiminobu et al. (2014) Nr4a3, a possibile oncogenic factor for neuroblastoma associated with CpGi methylation within the third exon. Int J Oncol 44:1669-77
Ambrosone, Christine B; Zirpoli, Gary; Ruszczyk, Melanie et al. (2014) Parity and breastfeeding among African-American women: differential effects on breast cancer risk by estrogen receptor status in the Women's Circle of Health Study. Cancer Causes Control 25:259-65
Röhm, Marc; Grimm, Melissa J; D'Auria, Anthony C et al. (2014) NADPH oxidase promotes neutrophil extracellular trap formation in pulmonary aspergillosis. Infect Immun 82:1766-77
Rohrbach, Daniel J; Muffoletto, Daniel; Huihui, Jonathan et al. (2014) Preoperative mapping of nonmelanoma skin cancer using spatial frequency domain and ultrasound imaging. Acad Radiol 21:263-70
Ambrosone, Christine B; Young, Allyson C; Sucheston, Lara E et al. (2014) Genome-wide methylation patterns provide insight into differences in breast tumor biology between American women of African and European ancestry. Oncotarget 5:237-48
O'Brien, Shalana; Golubovskaya, Vita M; Conroy, Jeffrey et al. (2014) FAK inhibition with small molecule inhibitor Y15 decreases viability, clonogenicity, and cell attachment in thyroid cancer cell lines and synergizes with targeted therapeutics. Oncotarget 5:7945-59

Showing the most recent 10 out of 517 publications